Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Hirosato Ebiike"'
Autor:
Nobuya Ishii, Yuko Aoki, Naoki Taka, Hirosato Ebiike, Toshiyuki Mio, Hidetoshi Shindoh, Kenji Morikami, Takehito Isobe, Hitoshi Sase, Kiyoaki Sakata, Toshihiko Fujii, Toshiyuki Tsukaguchi, Nukinori Akiyama, Yoshito Nakanishi
Supplementary Materials and Methods from The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c01026f8d65f8ae2359cbbdaf1c7f8e2
https://doi.org/10.1158/1535-7163.22501813
https://doi.org/10.1158/1535-7163.22501813
Autor:
Nobuya Ishii, Yuko Aoki, Naoki Taka, Hirosato Ebiike, Toshiyuki Mio, Hidetoshi Shindoh, Kenji Morikami, Takehito Isobe, Hitoshi Sase, Kiyoaki Sakata, Toshihiko Fujii, Toshiyuki Tsukaguchi, Nukinori Akiyama, Yoshito Nakanishi
Supplementary Figures S1-S7 and Table. S1: Determination of the binding mode of the FGFR inhibitor CH5183284/Debio 1347. S2: Effects of CH5183284/Debio 1347 and cediranib on in vitro VEGF-induced tube formation. S3: Kinase activity of FGFR2 WT, V564F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7730b1607e611f614d761c364343ce4c
https://doi.org/10.1158/1535-7163.22501816.v1
https://doi.org/10.1158/1535-7163.22501816.v1
Autor:
Toshiyuki Mio, Nobuya Ishii, Haruhiko Sato, Hiroshi Koyano, Hirosato Ebiike, Kiyomoto Ogasawara, Kiyoaki Sakata, Toshihiko Fujii, Yukako Tachibana, Yasuko Satoh, Masami Hasegawa, Hiromi Tanimura, Nukinori Akiyama, Kana Horiguchi-Takei, Takakazu Mizuno, Yoshito Nakanishi, Natsuki Hamanaka
Targeting genetic alterations of oncogenes by molecular-targeted agents (MTA) is an effective approach for treating cancer. However, there are still no clinical MTA options for many cancers, including esophageal cancer. We used a short hairpin RNA li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bbd4023fb895d8493a934a57935e6bd
https://doi.org/10.1158/0008-5472.c.6511173
https://doi.org/10.1158/0008-5472.c.6511173
Autor:
Toshiyuki Mio, Nobuya Ishii, Haruhiko Sato, Hiroshi Koyano, Hirosato Ebiike, Kiyomoto Ogasawara, Kiyoaki Sakata, Toshihiko Fujii, Yukako Tachibana, Yasuko Satoh, Masami Hasegawa, Hiromi Tanimura, Nukinori Akiyama, Kana Horiguchi-Takei, Takakazu Mizuno, Yoshito Nakanishi, Natsuki Hamanaka
Anti-proliferative activity against KYSE70 expressing mock, YES1-WT and SRC-WT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649c7c065bf23930b083930f4c156f76
https://doi.org/10.1158/0008-5472.22422285.v1
https://doi.org/10.1158/0008-5472.22422285.v1
Autor:
Yuko Aoki, Osamu Kondoh, Nobuya Ishii, Toshikazu Yamazaki, Yasushi Yoshimura, Keiichi Morita, Shino Kuramoto, Hirosato Ebiike, Jun Ohwada, Yukako Tachibana, Kiyoaki Sakata, Toshihiko Fujii, Hiromi Tanimura, Miyuki Yoshida, Hiroshi Tanaka
Purpose: The phosphatidylinositol 3-kinase (PI3K) pathway plays a central role in cell proliferation and survival in human cancer. PIK3CA mutations, which are found in many cancer patients, activate the PI3K pathway, resulting in cancer development a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662c38c75e05cc99955bf88044ca940c
https://doi.org/10.1158/1078-0432.c.6518331.v1
https://doi.org/10.1158/1078-0432.c.6518331.v1
Autor:
Toshiyuki Mio, Nobuya Ishii, Haruhiko Sato, Hiroshi Koyano, Hirosato Ebiike, Kiyomoto Ogasawara, Kiyoaki Sakata, Toshihiko Fujii, Yukako Tachibana, Yasuko Satoh, Masami Hasegawa, Hiromi Tanimura, Nukinori Akiyama, Kana Horiguchi-Takei, Takakazu Mizuno, Yoshito Nakanishi, Natsuki Hamanaka
Supplementary materials and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6532c4dee84d4dce36848778d941fa1a
https://doi.org/10.1158/0008-5472.22422303.v1
https://doi.org/10.1158/0008-5472.22422303.v1
Autor:
Toshiyuki Mio, Nobuya Ishii, Haruhiko Sato, Hiroshi Koyano, Hirosato Ebiike, Kiyomoto Ogasawara, Kiyoaki Sakata, Toshihiko Fujii, Yukako Tachibana, Yasuko Satoh, Masami Hasegawa, Hiromi Tanimura, Nukinori Akiyama, Kana Horiguchi-Takei, Takakazu Mizuno, Yoshito Nakanishi, Natsuki Hamanaka
Supplementary Figure S1. YES1 gene is amplified and YES1 expression is related to poor prognosis in esophageal cancer and lung cancer in clinical. Supplementary Figure S2. YES1 gene amplification including the upregulation of YES1 expression. Supplem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62eacf9b0f2cac370e83a2fdeb299d99
https://doi.org/10.1158/0008-5472.22422300
https://doi.org/10.1158/0008-5472.22422300
Autor:
Kiyomoto Ogasawara, Natsuki Hamanaka, Nukinori Akiyama, Takakazu Mizuno, Toshiyuki Mio, Toshihiko Fujii, Hirosato Ebiike, Kiyoaki Sakata, Hiroshi Koyano, Hiromi Tanimura, Masami Hasegawa, Nobuya Ishii, Kana Horiguchi-Takei, Yukako Tachibana, Haruhiko Sato, Yoshito Nakanishi, Yasuko Satoh
Publikováno v:
Cancer Research. 79:5734-5745
Targeting genetic alterations of oncogenes by molecular-targeted agents (MTA) is an effective approach for treating cancer. However, there are still no clinical MTA options for many cancers, including esophageal cancer. We used a short hairpin RNA li
Autor:
Jun Ohwada, Takuo Tsukuda, Hatsuo Kawada, Kohei Koyama, Hirosato Ebiike, Masao Tsukazaki, Yamamoto Shun, Kotaro Ogawa, Miyuki Yoshida, Kenji Morikami, Mitsuaki Nakamura, Nobuo Shimma, Kiyoshi Yoshinari
Publikováno v:
Bioorganic & Medicinal Chemistry. 24:2897-2906
Phosphoinositide 3-kinase (PI3K) is a promising anti-cancer target, because various mutations and amplifications are observed in human tumors isolated from cancer patients. Our dihydropyrrolopyrimidine derivative with a phenylurea moiety showed stron
Autor:
Natsuki, Hamanaka, Yoshito, Nakanishi, Takakazu, Mizuno, Kana, Horiguchi-Takei, Nukinori, Akiyama, Hiromi, Tanimura, Masami, Hasegawa, Yasuko, Satoh, Yukako, Tachibana, Toshihiko, Fujii, Kiyoaki, Sakata, Kiyomoto, Ogasawara, Hirosato, Ebiike, Hiroshi, Koyano, Haruhiko, Sato, Nobuya, Ishii, Toshiyuki, Mio
Publikováno v:
Cancer research. 79(22)
Targeting genetic alterations of oncogenes by molecular-targeted agents (MTA) is an effective approach for treating cancer. However, there are still no clinical MTA options for many cancers, including esophageal cancer. We used a short hairpin RNA li